Barclays raised the firm’s price target on Labcorp (LH) to $250 from $240 and keeps an Equal Weight rating on the shares. The company reported “steady momentum” and the guidance has “plenty of conservatism baked in,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp’s Resilience and Growth Potential: A Reliable Investment Choice Despite Revenue Miss
- Labcorp Holdings: Strong Q1 2025 Performance and Positive Outlook Justify Buy Rating
- Labcorp Reports Q1 2025 Earnings and Strategic Growth
- Labcorp’s Earnings Call Highlights Growth and Innovation
- Morning Movers: Hims & Hers skyrockets following obesity pact with Novo Nordisk